233 related articles for article (PubMed ID: 29517259)
1. Age-, sex-, and education-specific norms for an extended CERAD Neuropsychological Assessment Battery-Results from the population-based LIFE-Adult-Study.
Luck T; Pabst A; Rodriguez FS; Schroeter ML; Witte V; Hinz A; Mehnert A; Engel C; Loeffler M; Thiery J; Villringer A; Riedel-Heller SG
Neuropsychology; 2018 May; 32(4):461-475. PubMed ID: 29517259
[TBL] [Abstract][Full Text] [Related]
2. Effects of age, education and gender in the Consortium to Establish a Registry for the Alzheimer's Disease (CERAD)-Neuropsychological Assessment Battery for Cantonese-speaking Chinese elders.
Liu KP; Kuo MC; Tang KC; Chau AW; Ho IH; Kwok MP; Chan WC; Choi RH; Lam NC; Chu MM; Chu LW
Int Psychogeriatr; 2011 Dec; 23(10):1575-81. PubMed ID: 21729408
[TBL] [Abstract][Full Text] [Related]
3. Considering the base rates of low performance in cognitively healthy older adults improves the accuracy to identify neurocognitive impairment with the Consortium to Establish a Registry for Alzheimer's Disease-Neuropsychological Assessment Battery (CERAD-NAB).
Mistridis P; Egli SC; Iverson GL; Berres M; Willmes K; Welsh-Bohmer KA; Monsch AU
Eur Arch Psychiatry Clin Neurosci; 2015 Aug; 265(5):407-17. PubMed ID: 25555899
[TBL] [Abstract][Full Text] [Related]
4. The impact of the CERAD-NP on diagnosis of cognitive deficiencies in late onset depression and Alzheimer's disease.
Künig G; Jäger M; Stief V; Kaldune A; Urbaniok F; Endrass J
Int J Geriatr Psychiatry; 2006 Oct; 21(10):911-6. PubMed ID: 16927401
[TBL] [Abstract][Full Text] [Related]
5. CERAD (Consortium to Establish a Registry for Alzheimer's Disease) Neuropsychology Assessment Battery: 35 Years and Counting.
Fillenbaum GG; Mohs R
J Alzheimers Dis; 2023; 93(1):1-27. PubMed ID: 36938738
[TBL] [Abstract][Full Text] [Related]
6. The assessment of changes in cognitive functioning: age-, education-, and gender-specific reliable change indices for older adults tested on the CERAD-NP battery: results of the German Study on Ageing, Cognition, and Dementia in Primary Care Patients (AgeCoDe).
Stein J; Luppa M; Luck T; Maier W; Wagner M; Daerr M; van den Bussche H; Zimmermann T; Köhler M; Bickel H; Mösch E; Weyerer S; Kaufeler T; Pentzek M; Wiese B; Wollny A; König HH; Riedel-Heller SG
Am J Geriatr Psychiatry; 2012 Jan; 20(1):84-97. PubMed ID: 22183013
[TBL] [Abstract][Full Text] [Related]
7. Late preterm birth and neurocognitive performance in late adulthood: a birth cohort study.
Heinonen K; Eriksson JG; Lahti J; Kajantie E; Pesonen AK; Tuovinen S; Osmond C; Raikkonen K
Pediatrics; 2015 Apr; 135(4):e818-25. PubMed ID: 25733746
[TBL] [Abstract][Full Text] [Related]
8. Norms and the effects of demographic variables on a neuropsychological battery for use in healthy ageing Australian populations.
Collie A; Shafiq-Antonacci R; Maruff P; Tyler P; Currie J
Aust N Z J Psychiatry; 1999 Aug; 33(4):568-75. PubMed ID: 10483853
[TBL] [Abstract][Full Text] [Related]
9. Age, gender, and education norms on the CERAD neuropsychological battery in the oldest old.
Beeri MS; Schmeidler J; Sano M; Wang J; Lally R; Grossman H; Silverman JM
Neurology; 2006 Sep; 67(6):1006-10. PubMed ID: 17000969
[TBL] [Abstract][Full Text] [Related]
10. Performance on the CERAD neuropsychology battery of two samples of Japanese-American elders: norms for persons with and without dementia.
Fillenbaum GG; McCurry SM; Kuchibhatla M; Masaki KH; Borenstein AR; Foley DJ; Heyman A; Larson EB; White L
J Int Neuropsychol Soc; 2005 Mar; 11(2):192-201. PubMed ID: 15966108
[TBL] [Abstract][Full Text] [Related]
11. A total score for the CERAD neuropsychological battery.
Chandler MJ; Lacritz LH; Hynan LS; Barnard HD; Allen G; Deschner M; Weiner MF; Cullum CM
Neurology; 2005 Jul; 65(1):102-6. PubMed ID: 16009893
[TBL] [Abstract][Full Text] [Related]
12. The CERAD Neuropsychological Battery in Patients with Idiopathic Normal Pressure Hydrocephalus Compared with Normal Population and Patients with Mild Alzheimer's Disease.
Nerg O; Junkkari A; Hallikainen I; Rauramaa T; Luikku A; Hiltunen M; Jääskeläinen JE; Leinonen V; Hänninen T; Koivisto A
J Alzheimers Dis; 2021; 81(3):1117-1130. PubMed ID: 33896842
[TBL] [Abstract][Full Text] [Related]
13. The CERAD Neuropsychological Test Battery: norms from a Yoruba-speaking Nigerian sample.
Guruje O; Unverzargt FW; Osuntokun BO; Hendrie HC; Baiyewu O; Ogunniyi A; Hali KS
West Afr J Med; 1995; 14(1):29-33. PubMed ID: 7626529
[TBL] [Abstract][Full Text] [Related]
14. Norms for CERAD constructional praxis recall.
Fillenbaum GG; Burchett BM; Unverzagt FW; Rexroth DF; Welsh-Bohmer K
Clin Neuropsychol; 2011 Nov; 25(8):1345-58. PubMed ID: 21992077
[TBL] [Abstract][Full Text] [Related]
15. Comparison of verbal episodic memory measures: consortium to establish a registry for Alzheimer's disease--Neuropsychological Assessment Battery (CERAD-NAB) versus California Verbal Learning Test (CVLT).
Beck IR; Gagneux-Zurbriggen A; Berres M; Taylor KI; Monsch AU
Arch Clin Neuropsychol; 2012 Aug; 27(5):510-9. PubMed ID: 22718104
[TBL] [Abstract][Full Text] [Related]
16. A normative study of total scores of the CERAD neuropsychological assessment battery in an educationally diverse elderly population.
Han JY; Seo EH; Yi D; Sohn BK; Choe YM; Byun MS; Choi HJ; Kim SG; Park SY; Kim JW; Youn JC; Jhoo JH; Lee JH; Kim KW; Woo JI; Lee DY
Int Psychogeriatr; 2014 Nov; 26(11):1897-904. PubMed ID: 25075438
[TBL] [Abstract][Full Text] [Related]
17. Applicability of the CERAD neuropsychological battery to Brazilian elderly.
Bertolucci PH; Okamoto IH; Brucki SM; Siviero MO; Toniolo Neto J; Ramos LR
Arq Neuropsiquiatr; 2001 Sep; 59(3-A):532-6. PubMed ID: 11588630
[TBL] [Abstract][Full Text] [Related]
18. Normal ranges of neuropsychological tests for the diagnosis of Alzheimer's disease.
Berres M; Monsch AU; Bernasconi F; Thalmann B; Stähelin HB
Stud Health Technol Inform; 2000; 77():195-9. PubMed ID: 11187541
[TBL] [Abstract][Full Text] [Related]
19. CERAD test performance and cognitive impairment in Parkinson's disease.
Karrasch M; Laatu S; Martikainen K; Marttila R
Acta Neurol Scand; 2013 Dec; 128(6):409-13. PubMed ID: 23668316
[TBL] [Abstract][Full Text] [Related]
20. The Alzheimer's prevention initiative composite cognitive test score: sample size estimates for the evaluation of preclinical Alzheimer's disease treatments in presenilin 1 E280A mutation carriers.
Ayutyanont N; Langbaum JB; Hendrix SB; Chen K; Fleisher AS; Friesenhahn M; Ward M; Aguirre C; Acosta-Baena N; Madrigal L; Muñoz C; Tirado V; Moreno S; Tariot PN; Lopera F; Reiman EM
J Clin Psychiatry; 2014 Jun; 75(6):652-60. PubMed ID: 24816373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
